Introduction {#Sec1}
============

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone produced by the intestinal epithelial endocrine L cells through differential processing of proglucagon. It is secreted in response to a meal and plays an important role in glycemic control by acting on multiple organs and metabolic pathways. GLP-1 is responsible for 50--70% of the total postprandial insulin secretion in a glucose-dependent manner \[[@CR1]\]; its action on the pancreatic endocrine system also includes stimulation of insulin biosynthesis, reduction of glucagon secretion, modulation of insulin sensitivity of beta cells and, at least in animal models, a positive action on beta cell mass itself \[[@CR2]\]. Once secreted, GLP-1 is degraded within minutes.

The short in vivo half-life of GLP-1 receptor agonists (GLP-1RA) has historically represented a significant barrier to their routine clinical use, driving the search for new agents/formulations with more potent and longer-lasting activity. ExeOW is an extended release formulation of exenatide. Exenatide twice daily (ExeBID, Byetta^®^, Astra Zeneca) was the first GLP-1 receptor agonist approved for management of T2D. ExeOW requires only a once-weekly injection as compared to twice-daily injections of the ExeBID formulation. We reviewed data concerning treatment of T2D with ExeOW with special reference to its long-term efficacy, tolerability, and safety.

Methods {#Sec2}
=======

Studies for this review were identified through PubMed database searches (titles and abstracts) from inception until January 2015; search terms included GLP-1 receptor agonist, exenatide, slow release, long acting, once week, once-weekly, QW, OW---and other terms that could have been related to individual sections of this review. Neither language restriction nor a priori specific inclusion or exclusion criteria were used to filter the literature search except for selecting human studies only. Additional references were identified manually either from references listed in the studies selected through PubMed or from abstracts presented at 2014 American Diabetes Association (ADA) and European Association of the Studies of Diabetes (EASD) conferences. All review articles were considered while for clinical trials only studies lasting more than 3 months that included ExeOW as test drug or comparator were considered. Overall 90 papers were retrieved and eight were discarded.

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Indication and Use {#Sec4}
==================

ExeOW was initially approved in the European Union in 2011 for the treatment of T2D in combination with metformin, sulfonylurea, and thiazolidinedione when these do not provide adequate glycemic control. In the USA, ExeOW received FDA approval in 2012 for use in patients with T2D as an adjunct to diet and exercise. ExeOW is currently not approved for use in combination with basal insulin.

Formulation and Pharmacokinetics {#Sec5}
================================

Exenatide in its original subcutaneous formulation reaches its mean peak concentration within 2 h and has a terminal half-life of 2.4 h requiring twice-daily administration \[[@CR3]\].

ExeOW has been developed by adopting an encapsulation technique that slows the release of exenatide, allowing a once-weekly subcutaneous administration. The product is to be reconstituted just before injection. The pharmacokinetics of ExeOW have been assessed in one single-dose and two multiple-dose studies in patients with T2D \[[@CR4]\]. It is characterized by a multiphasic concentration--time profile due to the slow release of the drug in the bloodstream through the progressive dissolution of the polymeric matrix of the microspheres encapsulating exenatide \[[@CR5]\]. The process occurs in three stages: initial phase, diffusion, and final erosion release \[[@CR5]\]. Once injected, the microsphere hydrates and tends to form amalgams, initially releasing the drug molecules located on the surface or closer to the surface of the matrix. During the diffusion phase, the drug is released at a constant rate into the bloodstream, and finally during the erosion phase the matrix is completely dissolved. Consistent with this model of release, the initial time to maximum concentration after a single dose ExeOW is 2.1--5.1 h, and two subsequent phases of drug release follow several weeks later. After administration of the recommended dose of 2 mg, ExeOW minimal effective concentrations of greater than 50 pg/mL are attained in approximately 2 weeks and steady-state concentrations of approximately 300 pg/mL within 6--7 weeks \[[@CR6]\]. After treatment discontinuation, detectable blood levels of the drug are present for approximately 10 weeks \[[@CR5]\]. Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation.

ExeOW is commercially available in two delivery forms, namely a single-dose tray (BYDUREON^®^) and a single-dose, single-use, prefilled, dual-chamber pen that can be twisted for reconstitution and priming (BYDUREON Pen^®^) and supports ease of administration by patients and caregivers. This device has been positively evaluated by untrained and trained health care practitioners and patients; clinical studies confirm that it is easy for patients to learn how to use the dual-chamber pen \[[@CR7]\].

Antibody Formation {#Sec6}
==================

Similarly to ExeBID, ExeOW stimulates an immunogenic response with formation of antibodies which rarely achieve high titers, generally tend to decrease over time, and do not significantly alter drug activity or safety in most patients \[[@CR4], [@CR8], [@CR9]\].

A review of clinical trials comparing ExeOW versus ExeBID showed that low titers of anti-exenatide antibodies are common with both formulations (32% ExeBID, 45% ExeOW), but without manifest effects on drug efficacy, whereas higher titers of antibodies are less common (5% ExeBID, 12% ExeOW) and may be associated with an attenuated glycemic control \[[@CR10]\]. Anti-exenatide antibodies did not impact the safety of exenatide except for injection site reactions, which were more frequent in antibody-positive as compared to antibody-negative patients \[[@CR10]\].

Clinical effects {#Sec7}
================

Dose-finding studies \[[@CR4], [@CR6], [@CR9]\] have established 2 mg per week as the optimal dose for ExeOW in T2D patients: after 15 weeks of therapy 2 mg ExeOW achieved a superior glycemic control as compared to placebo or a lower dose of 0.8 mg/week, inducing an average reduction of HbA1c levels from baseline of 1.7%, with 86% of patients attaining HbA1c levels below the therapeutic target of 7%. A drop in HBA1c \[[@CR4]\] and also in fasting glucose levels was already attained at 3 weeks \[[@CR4], [@CR9]\]. In addition, while placebo and the lower ExeOW dose tested had no effect on body weight, the 2 mg per week dosage induced a significant weight reduction (−3.8 ± 1.4 kg). This dosage has been therefore further evaluated within randomized clinical trials (RCT) aimed at determining the activity and safety of ExeOW in T2D patients suboptimally controlled with other antidiabetic therapies. RCTs conducted with ExeOW are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Design of studies and glycemic outcomes in ExeOW randomized clinical trialsStudy \[Reference\]Study designSample sizeWeeksBackground therapyBaseline HbA1c (%)Kim et al. \[[@CR4]\]Randomized double-blind, phase 2, dose-finding vs. placeboPlacebo: 16\
ExeOW 0.8 mg: 16\
ExeOW 2.0 mg: 1515Diet/exercise ± METPlacebo: 8.6\
ExeOW 0.8 mg: 8.6\
ExeOW 2 mg: 8.3DURATION-1\
\[[@CR8]\]Randomized, open label, comparative vs ExeBID295\
ExeOW: 148\
ExeBID: 14730Diet/exercise ± MET, SFU, or TZD (or combos)ExeOW: 8.3\
ExeBID: 8.3DURATION-1\
1-year follow-up\
\[[@CR22]\]Uncontrolled, open labelExeOW: 258\
(130 from ExeBID arm)52Diet/exercise ± MET, SFU, or TZD (or combos)ExeOW: 8.3\
ExeBID: 8.2DURATION-1\
3-year follow-up\
\[[@CR23]\]Uncontrolled, open labelExeOW: 194156Diet/exercise ± MET, SFU, or TZD (or combos)8.2DURATION-1\
6-year follow-up \[[@CR17]\]Uncontrolled, open labelExeOW:136312Diet/exercise ± MET, SFU, or TZD (or combos)8.1DURATION-2 \[[@CR12]\]Randomized, prospective, double blind, double dummy, comparative vs. SITA vs. PIO514 (491)\
ExeOW: 170 (160)\
SITA: 172 (166)\
PIO: 172 (165)26METExeOW 8.6\
SITA: 8.5\
PIO: 8.5DURATION-3\
\[[@CR13]\]Randomized, prospective, open label comparative vs GLAR456\
ExeOW: 233\
GLAR: 22326MET ± SFUExeOW: 8.3\
GLAR: 8.3DURATION-3\
3-year follow-up\
\[[@CR18]\]As aboveExeOW: 140\
GLAR: 147156MET ± SFUExeOW: 8.2\
GLAR: 8.3DURATION-4\
\[[@CR11]\]Randomized, prospective, double blind, double dummy, comparative vs. MET, PIO, and SITA820 (696)\
ExeOW: 248\
MET: 246\
PIO: 163\
SITA: 16326Diet/exerciseExeOW: 8.5\
MET: 8.6\
PIO: 8.5\
SITA: 8.5DURATION-5\
\[[@CR14]\]Randomized, prospective, open label, comparative vs. ExeBID252\
ExeOW: 129\
ExeBID: 12324Diet/exercise ± MET, SFU, or TZD (or combos)ExeOW: 8.5\
ExeBID: 8.4DURATION-6\
\[[@CR15]\]Randomized, prospective, open label, non-inferiority vs. LIRA 1.8 mg911\
ExeOW: 461\
LIRA: 45026Diet/exercise ± MET, SFU, or TZD (or combos)ExeOW: 8.5\
LIRA: 8.4DURATION-8\
\[[@CR16]\]Multicenter, double-blind, randomized, active-controlled phase 3 trial695\
ExeOW + DAPA: 231\
ExeOW alone: 231\
DAPA alone: 23328Diet/exercise ± METExeOW + DAPA: 9.3\
ExeOW: 9.3\
DAPA: 9.3Study \[Reference\]HbA1c mean decrease from baseline (%)Patients achieving HbA1c \<7% (%)Patients achieving HbA1c \<6.5% (%)Baseline FPG mean (mmol/L)FPG mean decrease from baseline (mmol/L)Kim et al. \[[@CR4]\]Placebo: +0.4\
ExeOW 0.8 mg: −1.4\
ExeOW 2: −1.7 *p* \< 0.0001Placebo: 0\
ExeOW 0.8 mg: 36\
ExeOW 2 mg: 86NRPlacebo: 10.2\
ExeOW 0.8 mg: 10.3\
ExeOW 2 mg: 9.3Placebo: + 1.0\
ExeOW 0.8 mg: −2.4\
ExeOW 2 mg: −2.2 *p* \< 0.001DURATION-1\
\[[@CR8]\]ExeOW: −1.9\*\
Exe BID: −1.5\* *p* = 0.0023ExeOW: 77\
Exe BID: 61ExeOW: 49\
ExeBID: 25ExeOW: 9.6\
ExeBID: 9.2ExeOW: −2.3\*\
ExeBID: −1.4\* *p* \< 0.0001DURATION-1\
1-year follow-up\
\[[@CR22]\]From ExeOW: −2.0\*\
(vs. −2.1\* at week 30) pts from Exe BID: −2.0\*7154Pts from ExeOW: 9.6 pts from Exe BID: 9.2From ExeOW: −2.6\* from Exe BID: −2.4\*DURATION-1\
3-year follow-up\
\[[@CR23]\]−1.6\*55339.3−1.8\*DURATION-1\
6-year follow-up \[[@CR17]\]−1.6%\*46.3339.1−1.5DURATION-2 \[[@CR12]\]ExeOW: −1.5\*\
SITA: −0.9\*\
PIO: −1.2\*\
*p* \< 0.001 vs. SITA *p* = 0.0165 vs. PIOExeOW: 59\
SITA: 30\
PIO: 43\
*p* \< 0.0001 vs. SITA *p* \< 0.0015 vs. PIOExeOW: 40\
SITA: 17\
PIO: 28\
*p* \< 0.0001 vs. SITA\
*p* \< 0.0120 vs. PIOExeOW: 9.2\
SITA: 9.1\
PIO: 9.1ExeOW: −1.8\*\
SITA: −0.9\*\
PIO: −1.5\*\
*p* = 0.0038 vs. SITA *p* = NS vs. PIODURATION-3\
\[[@CR13]\]ExeOW: −1.5\*\
GLAR: −1.3\*\
*p* = 0.017ExeOW: 60\
GLAR: 48\
*p* = 0.01ExeOW: 35\
GLAR: 23\
*p* = 0.004ExeOW: 9.9\
GLAR: 9.7ExeOW: −2.1\*\
GLAR: −2.8\*\
(*p* = 0.001)DURATION-3\
3-year follow-up\
\[[@CR18]\]ExeOW: −1.09\*\
GLAR: −0.88\*\
*p* = 0.02ExeOW: 40\
GLAR: 33\
*p* = NSExeOW: 24\
GLAR: 15\
*p* = 0.023ExeOW: 9.6\
GLAR: 9.7ExeOW: −1.73\*\
GLAR: −2.65\*\
(*p* = 0.001)DURATION-4\
\[[@CR11]\]ExeOW: −1.53\*\
MET: −1.48\*\
PIO: −1.63\*\
SITA: −1.15\*\
*p* = NS vs. MET\
*p* = NS vs. PIO\
*p* = \<0.001 vs. SITAExeOW: 63\
MET: 55\
PIO: 61\
SITA: 43\
*p* = NS vs. MET\
*p* = NS vs. PIO\
*p* \< 0.002 vs. SITAExeOW: 49\
MET: 36\
PIO:42\
SITA: 26\
*p* = 0.004 vs. MET\
*p* = NS vs. PIO\
*p* \< 0.002 vs. SITAExeOW: 9.9\
MET: 10.0\
PIO: 9.8\
SITA: 9.7ExeOW: −2.3\*\
MET: −2.0\*\
PIO: −2.6\*\
SITA: −1.1\*\
*p* = NS vs. MET\
*p* = NS vs. PIO\
*p* = \<0.001 vs. SITADURATION-5\
\[[@CR14]\]ExeOW: −1.6\*\
ExeBID: −0.9\*\
*p* = 0.0001ExeOW: 58\
ExeBID: 30\
*p* \< 0.0001ExeOW: 41\
ExeBID: 16\
*p* \< 0.0001ExeOW: 9.6\
ExeBID: 9.3ExeOW: −1.9\*\
ExeBID: −0.7\*\
*p* = 0.0008DURATION-6\
\[[@CR15]\]ExeOW: −1.28\
LIRA: −1.48\
(*p* = 0.02)\
Tx difference 0.21% (95% CI = 0.08--0.33%)ExeOW: 9.6\
LIRA: 9.8ExeOW: −1.8\
LIRA: −2.1\
(*p* = 0.0001)DURATION-8\
\[[@CR16]\]ExeOW + DAPA: −2.0\
ExeOW: −1.6\
DAPA: −1.4ExeOW + DAPA: 45\
ExeOW: 27\
DAPA: 19ExeOW + DAPA: 30\
ExeOW: 19\
DAPA: 10ExeOW + DAPA: 11.0\
ExeOW: 10.8\
DAPA: 10.9ExeOW + DAPA: −2.30\
ExeOW: −1.19\
DAPA: −1.46*EXEOW* exenatide once weekly, *FPG* fasting plasma glucose, *GLAR* insulin glargine, *DET* insulin detemir, *SITA* sitagliptin, *MET* metformin, *PIO* pioglitazone, *SFU* sulfonylurea, *TZD* thiazolidinediones, *LIRA* liraglutide, *DAPA* dapagliflozin,*NS* not significant\* Least squares mean

A cluster of studies named DURATION (Diabetes therapy Utilization: Researching changes in A1C, weight and other factors Through Intervention with exenatide ONce weekly) evaluated the efficacy and safety of ExeOW when administered in patients with T2D either as monotherapy in adjunct to diet and exercise \[[@CR11]\] or as an add-on to oral antidiabetic agents including metformin alone \[[@CR12]\] or in combination with sulfonylurea and/or thiazolidinedione and sodium glucose transporter 2 inhibitor (SGLT2-I) dapagliflozin \[[@CR8], [@CR13]--[@CR16]\].

Two studies compared ExeOW to ExeBID \[[@CR8], [@CR14]\]. Further studies evaluated ExeOW versus the oral DPP-4 inhibitor sitagliptin, pioglitazone \[[@CR11], [@CR12]\], metformin \[[@CR11]\], basal insulin glargine (GLAR) \[[@CR13]\], or a GLP-1 analogue for daily use, liraglutide \[[@CR15]\]. All of these studies had HbA1c mean decrease from baseline as primary endpoint.

While in most of these studies therapy lasted for 24--30 weeks, additional important long-term efficacy and safety data can be drawn from the non-comparative extensions of the DURATION-1 trial (up to 6 years) \[[@CR17]\] and the comparative 3-year extension of the DURATION-3 trial \[[@CR18]\].

ExeOW has been tested in Asian populations, in which it showed efficacious glucose and weight control; safety and tolerability were consistent with observations in non-Asian patients \[[@CR19]\]. T2DM in Asian patients is characterized by beta cell dysfunction rather than insulin resistance \[[@CR20], [@CR21]\].

Effects on Glycemic Control {#Sec8}
---------------------------

### ExeOW as Monotherapy {#Sec9}

Only one RCT has assessed the efficacy of ExeOW when used as monotherapy (DURATION-4 \[[@CR11]\]). This RCT was designed to prove non-inferiority in comparison with metformin, pioglitazone, and sitagliptin in T2D uncontrolled by diet and physical activity. The patients were exenatide naïve and were followed for 26 weeks. As shown in Table [1](#Tab1){ref-type="table"}, ExeOW attained a glycemic control that was significantly superior to that achieved with the DPP-4 inhibitor sitagliptin and non-inferior to that achieved with metformin. In contrast with results obtained in a previous study \[[@CR12]\] where ExeOW proved to be more effective than pioglitazone as an add-on to metformin, criteria for non-inferiority versus pioglitazone monotherapy were not met. The authors hypothesized that different baseline characteristics of the patient populations, such as the mean duration of diabetes, could have been confounding factors contributing to such a result.

ExeOW as Add-on to Other Antidiabetic Therapies {#Sec10}
-----------------------------------------------

### ExeOW Compared to ExeBID {#Sec11}

Two studies compared ExeOW to ExeBID testing the single-dose tray \[[@CR8], [@CR14]\].

The DURATION-1 study \[[@CR8]\] was designed to test non-inferiority of ExeOW as compared to ExeBID in patients receiving metformin, sulfonylurea, or thiazolidinedione monotherapy or in combination, based on the difference in the reduction of HbA1c (95% CI upper limit of the difference \<0.4%). Treatment within the initial randomized portion of the study had a duration of 30 weeks but subsequent cohorts of patients entered long-term uncontrolled extensions of the study up to 7 years: data up to 6 years have been published to date \[[@CR17]\].

At week 30 ExeOW attained superior glycemic control as compared to ExeBID in terms of mean HbA1C decrease (−1.9 vs −1.5%, *p* = 0.0023), proportion of patients attaining HbA1c \<7% (77% vs 61%) or \<6.5% (49% vs 25%), and mean FBG decrease (−2.3 vs −1.4 mmol/L, *p* \< 0.0001) (Table [1](#Tab1){ref-type="table"}). At 1-year follow-up \[[@CR22]\], while patients initially treated with ExeOW maintained results obtained at week 30, those switched from ExeBID further improved glycemic control similarly to the group treated with ExeOW upfront (Table [1](#Tab1){ref-type="table"}).

At 3 years, antidiabetic therapy was unchanged in 83% of patients and glycemic control was generally maintained: 55% and 33% of patients had HbA1c levels \<7% or ≤6.5%, respectively \[[@CR23]\].

The slight progressive trend upward in HbA1c and FPG levels and the reduced proportion of patients attaining HbA1c below target levels noted after the first year of ExeOW treatment \[[@CR23]\] were probably due to the natural progression of the disease. This interpretation is corroborated by findings from another RCT (DURATION-3) in which, around week 84 of therapy, a similar rise in HbA1c levels was observed both in patients treated with ExeOW and in those receiving GLAR \[[@CR24]\].

Recently, 6-year follow-up data have been reported from 136 patients, 53% of those who entered in the open-ended assessment period of the DURATION-1 study \[[@CR17]\]. Prolonged treatment with ExeOW allowed a persistent and meaningful long-term glycemic control with reduction in HbA1c levels from baseline similar to that achieved at previous follow-ups (Table [1](#Tab1){ref-type="table"}).

The superiority of ExeOW over ExeBID has been also confirmed in a twin RCT conducted in the USA in the same target population patients \[[@CR14]\] (Table [1](#Tab1){ref-type="table"}).

### ExeOW Compared to Pioglitazone and Sitagliptin {#Sec12}

ExeOW has been demonstrated to be more effective than pioglitazone and the oral DPP-4 sitagliptin as add-on treatment to metformin in a 26-week RCT testing the superiority of ExeOW in terms of HbA1c change from baseline \[[@CR12]\]. ExeOW induced a significantly greater reduction in HbA1c from baseline as compared to both pioglitazone and sitagliptin. FPG mean decrease was also more pronounced with ExeOW, reaching statistical significance when compared to sitagliptin (Table [1](#Tab1){ref-type="table"}).

Efficacy of ExeOW associated with thiazolidinedione (rosiglitazone or pioglitazone) has also been tested in a non-comparative trial primarily designed to assess ExeOW tolerability and safety in 134 subjects (44 exenatide naïve and 90 switched from ExeBID); metformin background therapy was allowed \[[@CR25]\]. Mean decrease in ExeOW-naïve patients was −0.7%, while patients switching from ExeBID to ExeOW achieved a further improvement of −0.4%.

### ExeOW Compared to Insulin {#Sec13}

Treatment with ExeOW has been compared to GLAR in a randomized, superiority study conducted in patients with suboptimal glycemic control with oral antidiabetic drugs \[[@CR13]\]. GLAR was titrated, starting from an initial dose of 10 IU, to achieve an FPG between 4 and 4.5 mmol/L. During the initial 26-week portion of the study, the change in HbA1c was significantly greater in patients taking ExeOW than in those treated with GLAR and, significantly, more patients treated with ExeOW achieved HbA1c targets of 7%. As expected, GLAR produced significantly greater reductions in FPG than ExeOW, while ExeOW produced significantly greater reductions in postprandial glucose excursions than GLAR (*p* = 0.001 after morning meals and *p* = 0.033 after evening meals).

Three-year follow-up data from this study \[[@CR18]\] confirm the sustained long-term activity of ExeOW. Throughout the 3-year treatment period, mean HbA1c was lower in patients given ExeOW than in those given GLAR; at 3 years the mean decrease from baseline in HbA1c was still significantly greater in patients treated with ExeOW and more patients treated with ExeOW achieved HbA1c targets (Table [1](#Tab1){ref-type="table"}). Monitoring of FPG confirmed lower concentrations throughout the study in patients given GLAR, with significantly greater reductions at 3 years.

Randomized data are also available showing superiority of treatment with ExeOW over DET in patients with suboptimal glycemic control with metformin with or without sulfonylurea \[[@CR26]\] (Table [1](#Tab1){ref-type="table"}). DET was administered once or twice daily and titrated to achieve an FPG of 5.5 mmol/L. This study used a composite primary endpoint, i.e., percentage of patients achieving a target HbA1c of ≤7.0% showing a decrease of ≥1 kg in body weight. A 6-month treatment with ExeOW resulted in a greater proportion of patients achieving the target in comparison with DET (44.1% vs. 11.04%, *p* \< 0.0001).

Whereas treatment with long-acting basal insulin analogue acts predominantly on fasting blood glucose, GLP-1 agonists---including ExeOW---also have an important action on both fasting and postprandial blood glucose \[[@CR4], [@CR8], [@CR9]\]. Vora and colleagues \[[@CR27]\] recently analyzed results from three RCT comparing ExeOW versus GLAR (two studies) or DET (one study) in terms of effects on fasting and postprandial blood glucose levels considering different indexes of daily glycemic variability including mean amplitude of glucose excursions (MAGE), blood glucose range and variability. While confirming the superior activity of ExeOW in reducing HbA1c, this analysis indicated that ExeOW reduces blood glucose variability and postprandial glucose levels as compared to GLAR (*p* \< 0.001) and DET (*p* = NS).

### ExeOW Compared to Liraglutide {#Sec14}

Non-inferiority of ExeOW as compared to the once-daily GLP-1 analogue liraglutide 1.8 mg (LIRA) was tested in a large RCT which used more stringent criteria for non-inferiority than those used in prior non-inferiority studies (upper bound of the 95% CI of the difference in change of HbA1c \<0.25% as compared to 0.4% in other ExeOW non-inferiority studies) \[[@CR15]\]. Both once-daily liraglutide and once-weekly exenatide led to improvements in glycemic control, with greater reductions noted with liraglutide. Change in HbA1c at endpoint was significantly greater in LIRA than in ExeOW groups, −1.48% vs.−1.28%, *p* = 0.02) with the treatment difference (0.21%, 95% CI 0.08--0.33) not meeting predefined non-inferiority criteria.

Scott and colleagues performed a network meta-analysis of 22 RCT conducted with ExeOW or liraglutide (1.2, 1.8 mg) aimed at evaluating their relative efficacy in lowering HbA1c: estimation of mean differences in HbA1c relative to placebo or each other and probability rankings identified no meaningful differences, suggesting similar glycemic control \[[@CR28]\].

### ExeOW in Combination with Dapagliflozin {#Sec15}

GLP-1RA and SGLT2-I agents reduce hyperglycemia, weight, and improve cardiovascular risk factors by complementary mechanisms. DURATION-8 is the first phase III study of a GLP-1RA (ExeOW) and SGLT2-I (dapagliflozin, DAPA) combination in T2D patients. After 28 weeks, the change in baseline HbA1c was −2.0% (95% CI −2.1 to −1.8) in the ExeOW plus DAPA group, −1.6% (−1.8 to −1.4) in the ExeOW group, and −1.4% (−1.6 to −1.2) in the DAPA group. ExeOW plus DAPA significantly reduced HbA1c from baseline to week 28 compared with ExeOW alone (−0.4% \[95% CI −0.6 to −0.1\]; *p* = 0.004) or DAPA alone (−0.6% \[−0.8 to −0.3\]; *p* \< 0.001) \[[@CR16]\].

Non-Glycemic Effects {#Sec16}
--------------------

### Effects on Body Weight {#Sec17}

Both exenatide formulations, ExeBID and ExeOW, were demonstrated to be negative regulators of appetite and food intake, and these effects result in an appreciable body weight reduction \[[@CR8], [@CR29]\]. The underlying mechanism is complex and is the result of combined actions on different systems including the gastrointestinal and the central nervous systems (CNS) \[[@CR30]\]. The gastrointestinal effects of GLP-1 and its agonists, including exenatide, are mediated by inhibition of gastrointestinal motility and secretion \[[@CR31]\]. They are involved in the "ileal brake" mechanism causing slowdown of progression of food in the gastrointestinal tract with consequent lowering of postprandial blood glucose levels and increased sense of satiety. However, the effects on the gastrointestinal system do not appear to be the main mechanism responsible for body weight decrease during ExeOW therapy. In animal models GLP-1 receptors have been found in different regions of the brain, with high density in areas implicated in the regulation of food intake \[[@CR32]\]. Exenatide is able to cross the blood--brain barrier when administered peripherally \[[@CR33]\] and, therefore, can act directly on the CNS. It also exerts an indirect action by activating GLP-1 receptors expressed on vagal afferents \[[@CR34]\].

In all RCTs, treatment with ExeOW consistently reduced body weight (Fig. [1](#Fig1){ref-type="fig"}), except for one small dose-finding study conducted in Japanese patients where a neutral effect on weight was observed, possibly as a result of leanness \[[@CR35]\] of the Japanese patients enrolled in this study (30 subjects, mean BMI around 26 kg/m^2^).Fig. 1Durability in HbA1c and body weight decrease from DURATION-1 and DURATION-3 studies. Mean HbA1c (**a**) and body weight (**b**) observed after 6 and 3 years of treatment with ExeOW within DURATION-1 and DURATION-3 study extensions, respectively

ExeOW-induced weight loss was dose dependent \[[@CR4]\], durable, and consistent over time \[[@CR17]--[@CR23]\]. After 6 months of therapy, mean body weight decrease ranged from -2.0 kg \[[@CR10]\] to −3.7 kg \[[@CR8]\] and was significantly more marked than with pioglitazone and sitagliptin \[[@CR12]\] while, as expected, GLAR \[[@CR13], [@CR18]\] induced a significant body weight increase (Table [3](#Tab3){ref-type="table"}). After 5 and 6 years of ExeOW treatment, the reduction in body weight was 3 and 4.2 kg, respectively \[[@CR17], [@CR36]\] (Fig. [1](#Fig1){ref-type="fig"}).

A pooled analysis from eight studies indicates that ExeOW improves glycemic control independent of weight change but the magnitude of improvement increases with increasing weight loss \[[@CR35]\].

Effects on Cardiovascular System {#Sec18}
--------------------------------

In the diabetic population, GLP-1 agonists, including exenatide, have different and peculiar effects on the cardiovascular system, including modification of cardiovascular risk factors, hemodynamic effects on cardiac function, and cardioprotective effects \[[@CR37]\]. The effects of exenatide on the cardiovascular system were evaluated in both preclinical models and in clinical trials. A summary of available evidence is provided below.

### Changes of Biochemical Indicators of Cardiovascular Risk {#Sec19}

The effect of ExeOW on the lipid profile has been extensively studied in five RCTs and their long-term extensions, when applicable. Chiquette and colleagues found that treatment with ExeOW modifies the lipoprotein pattern, reducing apolipoprotein B and ApoB/ApoA ratio \[[@CR38]\].

A positive effect on the lipid profile has been demonstrated with ExeOW after 6-month or 1-year treatment in two RCT versus ExeBID \[[@CR8], [@CR11], [@CR17], [@CR22]\] which had been previously demonstrated to induce a significant improvement of triglycerides, HDL-C, and high sensitivity C-reactive protein levels (*p* \< 0.005 for all parameters) as compared to glimepiride in patients receiving metformin \[[@CR39]\]. Exe-LAR induced a decrease in plasma triglycerides up to 15% at 1-year, a slight decrease in total cholesterol, and a slight increase in HDL levels \[[@CR8]\] (Table [2](#Tab2){ref-type="table"}). These positive effects persisted for up to 6 years \[[@CR17]\] (Table [2](#Tab2){ref-type="table"}). The effect of ExeOW on the lipid profile was comparable to that of LIRA in an RCT \[[@CR15]\].Table 2Lipids and blood pressure in ExeOW randomized clinical trialsStudy \[Reference\]Baseline TG mean (mmol/L)TG mean decrease from baseline (%) (mmol/L)Baseline T-CHOL (mmol/L)T-CHOL mean decrease\
from baseline (mmol/L)Baseline HDL\
Mean (mmol/L)HDL mean decrease from baseline (mmol/L)DURATION-1 \[[@CR8]\]ExeOW: 1.88\
ExeBID: 1.78ExeOW: 15%\*\
ExeBID: −11%\*ExeOW: 4.49\
ExeBID: 4.72ExeOW: −0.31\*\
ExeBID: −0.1\*ExeOW: 1.14\
ExeBID: 1.20ExeOW: −0.02\*\
ExeBID: −0.03\*DURATION-1 1-year follow-up \[[@CR22]\]ExeOW: 1.88\
ExeBID: 1.78ExeOW: −15%\*\
ExeBID: −13%\*ExeOW: 4.39\
ExeBID: 4.65ExeOW: −0.25\*\
ExeBID: −0.23\*ExeOW: 1.13\
ExeBID: 1.18ExeOW: −0.01\*\
ExeBID: −0.04\*DURATION-1 3-year follow-up \[[@CR23]\]1.7−12%\*4.5−0.26\*1.2+0.03\*DURATION-1 6-year follow-up \[[@CR17]\]1.7−5.2%\*4.5−0.26\*1.2+0.07\*DURATION-2 \[[@CR12]\]ExeOW: 1.9\
SITA: 1.9\
PIO: 2.2ExeOW: −5%\
SITA: −5%\
PIO: −16% (*p* = 0.006)ExeOW: 4.5\
SITA: 4.6\
PIO: 4.9Exe-LAR: →\
SITA: ↑\
PIO: ↑\
+0.16\*ExeOW: 1.1\
SITA: 1.1\
PIO: 1.1ExeOW: +0.05\*\
SITA: +0.05\*\
PIO: +0.16\*DURATION-3 \[[@CR13]\]ExeOW: 1.85\
GLAR: 1.82ExeOW: −4%\
GLAR: −11%ExeOW: 4.82\
GLAR: 4.81ExeOW: −0.12\*\
GLAR: −0.04\* *p* \< 0.05ExeOW: 1.2\
GLAR: 1.19ExeOW: 0.0\
GLAR: −0.01 *p* = NSDURATION-3 3-year follow-up \[[@CR18]\]ExeOW: 1.86\
GLAR: 1.81ExeOW: + 2%\
GLAR: −3% *p* = NSExeOW: 4.82\
GLAR: 4.81ExeOW: −0.13\*\
GLAR: −0.07\* *p* = NSExeOW: 1.20\
GLAR: 1.19ExeOW: +0.05\
GLAR: +0.05 *p* = NSDURATION-4 \[[@CR11]\]NRNo significant changeNRNo significant changeNRNo significant changeDURATION-5 \[[@CR14]\]ExeOW: 1.9\
ExeBID: 1.7ExeOW: (−0.011\*)\
ExeBID: (−0.10\*)ExeOW: 4.7\
ExeBID: 5.0ExeOW:−0.39\*\
ExeBID: +0.01\*ExeOW: 1.11\
ExeBID: 1.18ExeOW: 0\*\
ExeBID: + 0.03\*DURATION-6 \[[@CR15]\]NRNRExeOW: 4.5\
LIRA: 4.6ExeOW: −0.06\*\
LIRA: −0.15\*ExeOW: 1.1\
LIRA: 1.2ExeOW: +0.02\*\
LIRA: +0.02\*Study \[Reference\]Baseline LDL-C mean (mmol/L)LDL-C mean decrease from baseline (mmol/L)Baseline SBP mean (mmHg)SBP\
mean decrease from baseline (mmHg)Baseline DBP mean (mmHg)DBP\
mean decrease from baseline (mmHg)DURATION-1 \[[@CR8]\]ExeOW: 2.37\
ExeBID: 2.6ExeOW: −0.13\
ExeBID: +0.03ExeOW: 127.8\
ExeBID: 129.5ExeOW: −4.7\*\
ExeBID: −3.4\*ExeOW: 77.7\
ExeBID: 79.6ExeOW: −1.7\*\
ExeBID: −1.7\*DURATION-1 1-year follow-up \[[@CR22]\]ExeOW: 2.3\
ExeBID: 2.53ExeOW: −0.08\*\
ExeBID: −0.07\*NRExeOW: −6.2\*\
ExeBID: −3.8\*NRExeOW: −2.8\*\
ExeBID: −1.8\*DURATION-1 3-year follow-up \[[@CR23]\]2.4−0.18\*129−2.14\*78−2.0\* (*p* \< 0.05)DURATION-1 6-year follow-up \[[@CR17]\]2.4−0.25\*129+1.7\*78−1.2\*DURATION-2 \[[@CR12]\]ExeOW: 2.7\
SITA: 2.7\
PIO: 2.9No significant differences between the 3 groupsExeOW: 126\
SITA: 126\
PIO: 127ExeOW vs. SITA: *p* = 0.005 (Normal BP)\
*p* = 0.009 (hypertensive pts)NRNo significant differences between the 3 groupsDURATION-3 \[[@CR13]\]ExeOW: 2.68\
GLAR: 2.68ExeOW −0.05\
GLAR +0.04 *p* = NSExeOW: 135\
GLAR: 133ExeOW: −3\
GLAR: −1\
*p* = 0.05ExeOW: 81\
GLAR: 80ExeOW: −1\
GLAR: −1\
*p* = NSDURATION-3 3-year follow-up \[[@CR18]\]ExeOW: 2.68\
GLAR: 2.68ExeOW −0.17\
GLAR −0.13 *p* = NSExeOW: 135\
GLAR: 133ExeOW: −2\
GLAR: +2ExeOW: 81\
GLAR: 80ExeOW: −2\
GLAR: −2DURATION-4 \[[@CR11]\]NRNo significant changeNRExeOW: −1.3\*\
MET: NR\
PIO −1.7\*\
SITA −1.8\*NRExeOW: NR\
MET: NR\
PIO: −2.5\
SITA: NRDURATION-5 \[[@CR14]\]ExeOW: 2.7\
ExeBID: 3.1ExeOW: −0.16\
ExeBID: +0.07Abnorm Bas. BP\
ExeOW: 142\
ExeBID: 139\
Normal Bas. BP\
ExeOW: 118\
ExeBID: 118Abnorm. Bas. BP\
ExeOW: −7.9\*\
ExeBID: −7.7\*\
Normal Bas. BP\
ExeOW: + 1.6\*\
ExeBID: +5.0\*Abnorm. Bas. BP\
ExeOW: 81\
ExeBID: 82\
Normal Bas. BP\
ExeOW: 74\
ExeBID: 74Abnorm. Bas. BP\
ExeOW: −0.4\*\
ExeBID: −2.3\*\
Normal Bas. BP\
ExeOW: +0.6\*\
ExeBID: +1.8\*DURATION-6 \[[@CR15]\]ExeOW: 2.5\
LIRA: 2.5ExeOW: −0.05\*\
LIRA: −0.09\*ExeOW: 132\
LIRA: 134ExeOW: −2.5\*\
LIRA: −3.4\*ExeOW: 79\
LIRA: 80ExeOW: −0.5\*\
LIRA: −0.5\**EXEOW* exenatide once weekly, *FPG* fasting plasma glucose, *GLAR* insulin glargine, *DET* insulin detemir, *SITA* sitagliptin, *MET* metformin, *PIO* pioglitazone, *LIRA* liraglutide,*NR* not reported,*NS* not significant\* Least squares mean

### Hemodynamic Effects {#Sec20}

A positive effect of ExeOW on systolic blood pressure (SBP) has been documented across several RCTs (Table [2](#Tab2){ref-type="table"}): a statistically significant decrease in SBP was demonstrated as compared to sitagliptin \[[@CR12]\], GLAR \[[@CR16], [@CR18]\], and DET \[[@CR26]\]. Equivocal results were instead reported regarding diastolic blood pressure (DBP) values (Table [2](#Tab2){ref-type="table"}), with statistically significant results reported at 3-year follow-up in a single study \[[@CR18]\]. A meta-analysis which considered 12 RCTs conducted with GLP-1 receptor agonists reported a consistent reduction in SBP in comparison with controls \[[@CR40]\].

A positive, although small, chronotropic effect (2--4 bpm) was observed consistently in different studies conducted with ExeOW \[[@CR11], [@CR17]\]. The relationship between the observed changes in blood pressure and heart rate have not yet been clarified; more data are required to draw conclusions as regards the impact of these hemodynamic effects in terms of cardiac outcomes \[[@CR41]\].

Finally, studies to evaluate the effects of treatment with exenatide on prolongation of QTc interval have been conducted only using ExeBID: no appreciable effect has been demonstrated \[[@CR42]--[@CR44]\].

### Cardioprotective Effects {#Sec21}

Activation of the GLP-1 receptor exerts, at least in vitro, a protective function on cardiomyocytes by increasing glucose uptake and acting on the metabolic pathways of oxidative stress and apoptosis \[[@CR45]\]; in addition, preclinical studies suggest that GLP-1 receptors located in the heart and vasculature may play a protective role with respect to cardiovascular disease \[[@CR46], [@CR47]\].

The possible use of exenatide in interventional cardiology has been investigated. In a porcine model experimental exenatide reduced ischemic injury in terms of size and deterioration of cardiac function \[[@CR48]\]. In a clinical study involving patients with ST elevation myocardial infarction, intravenous infusion of low-dose exenatide during reperfusion and for the following 6 h induced a 30% reduction of the myocardial infarct area at 3 months in the subset of patients with shorter lag between the first medical contact and the first inserted balloon \[[@CR49]\].

Further supporting evidence can be derived from a prospective placebo-controlled RCT assessing the safety and feasibility of high-dose exenatide in patients with a first ST elevation myocardial infarction undergoing percutaneous coronary intervention: administration of high doses of exenatide was safe and feasible with a trend towards a smaller infarct size at 4 months as a percentage of the area at risk in patients with thrombolysis in myocardial infarction (TIMI) 0 or 1 flow receiving exenatide \[[@CR50]\].

A large randomized, placebo-controlled study (EXSCEL) is currently ongoing in patients with T2D to assess the impact of ExeOW as add-on to usual care on major cardiovascular outcomes as measured by a composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke; the study will recruit 14,000 patients and relevant results are expected in 2018 \[[@CR51]\].

Tolerability {#Sec22}
------------

The most common treatment-emergent adverse events reported in RCTs with ExeOW are summarized in Table [4](#Tab4){ref-type="table"}. The most frequent events associated with ExeOW therapy are gastrointestinal (nausea, vomiting, diarrhea) and injection site reactions (nodules, pruritus, erythema). These events occur more frequently in the initial phase of treatment, with incidence decreasing over time as indicated by the analysis of the proportion of patients reporting selected symptoms over time \[[@CR15], [@CR18]\], and further confirmed by the analysis of the annual event rates over a 6-year follow-up within the DURATION-1 study \[[@CR17]\] (Table [5](#Tab5){ref-type="table"}). The overall withdrawal rate in RCTs ranged from 6.3% to 25.3%, with 2.4% to 11% of patients discontinuing treatment because of an adverse event, mainly due to gastrointestinal side effects (Table [3](#Tab3){ref-type="table"}).Table 3Body weight decrease in ExeOW randomized clinical trials of at least 26 weeksExeOW StudyLS mean body weight decrease (kg)ExeOWExeBIDSITAPIOGLARMETPIOSITALIRADETDURATION-1 \[[@CR8]\]−3.7−3.6DURATION-2 \[[@CR12]\]−2.3−0.3 §2.8 ¶DURATION-3 \[[@CR13]\]−2.61.4\*DURATION-4 \[[@CR11]\]−2−21.5\*0.3\*DURATION-5 \[[@CR14]\]−2.3−1.4DURATION-6 \[[@CR15]\]−2.7−3.6*EXEOW* exenatide once weekly, *EXEBID* exenatide twice a day, *SITA* sitagliptin, *PIO* pioglitazone, *GLAR* insulin glargine, *MET* metformin, *LIRA* liraglutide, *DET* insulin detemir\* *p* \< 0.001, § *p* = 0.0002, ¶ *p* \< 0.0001

Gastrointestinal side effects and withdrawals due to adverse events reported with ExeOW, though generally more frequent as compared to oral antidiabetic agents or insulin, were markedly lower than with ExeBID \[[@CR52]\] or with LIRA (Table [4](#Tab4){ref-type="table"}). Though reactions at the injection site were more frequent with ExeOW, pruritus and erythema decreased significantly over time; injection site nodules, infrequent during the initial phase, were not reported during long-term treatment \[[@CR17]\] (Table [5](#Tab5){ref-type="table"}).Table 4Overview of treatment-emergent adverse events in ExeOW randomized clinical trials of at least 26 weeksStudy\
\[Ref\]Adverse event (%)Withdrawal rate (%)TxsNauseaVomitingDiarrheaInjection site reactionsUpper respiratory infectionsMinor hypoglycemiaDue to AEOverallDURATION-1 \[[@CR8]\]ExeOW26.410.813.322.38.15.46.113.5ExeBID34.518.613.111.717.26.24.811.6DURATION-2 \[[@CR12]\]ExeOW24111810716.325.3SITA10210101633.016.3PIO531072013.623.8DURATION-3 \[[@CR13]\]ExeOW134913n/a8510.3GLAR1142n/a2616.3DURATION-4 \[[@CR11]\]ExeOW11.34.810.910.57.75.22.415.3MET6.93.312.610.24.542.413.1SITA3.71.85.56.79.810.614.1PIO4.33.13.73.78.63.13.118.4DURATION-5 \[[@CR14]\]ExeOW144.79.31373.9515.5ExeBID358.94.1104.13.3522.8DURATION-6 \[[@CR15]\]ExeOW94610310.82.6NRLIRA211113138.95.3NRDAVIES et al. \[[@CR22]\]ExeOW1814171NR611NRDET29110NR75NRINAGAKI et al. \[[@CR81]\]ExeOW27188.834.925.69.85.1NRGLAR342.4021.220.82.8NR*EXEOW* exenatide once weekly, *FPG* fasting plasma glucose, *GLAR* insulin glargine, *DET* insulin detemir, *SITA* sitagliptin, *MET* metformin, *PIO* pioglitazone, *LIRA* liraglutide,*NR* not reported Table 5Annual adverse event rates during treatment with ExeOW (treatment-emergent adverse events with 10% or greater incidence) (modified from Henry et al. \[[@CR17]\])Adverse event30-Week annual event rate\
(%)Week 312 annual event rate (%)Nausea84.67.6Injection site pruritus51.01.6Diarrhea37.310.2Vomiting36.16.9Urinary tract infection22.47.6Constipation19.92.8Nasopharyngitis18.716.0Upper respiratory infection16.217.2Viral gastroenteritis14.93.3Arthralgia12.46.7Sinusitis8.710.4Back pain8.75.7Hypertension6.24.3Cough6.23.2Bronchitis5.04.7Pain in extremity2.55.0Muscoloskeletal pain2.54.2

Hypoglycemia {#Sec23}
------------

Major hypoglycemia has not been observed in association with ExeOW therapy. At the recommended dosage, minor (defined as plasma glucose concentration \<3 mmol/L), symptomatic hypoglycemia has been reported in 1--11% of patients (Table [4](#Tab4){ref-type="table"}). Its frequency and severity are higher when ExeOW is associated with sulfonylurea \[[@CR53]\].

Safety {#Sec24}
------

Over the past years there have been concerns for the long-term safety of incretin-based therapies, specifically as regards their potential to promote rare events such as acute pancreatitis, to initiate histological changes suggesting chronic pancreatitis, including associated preneoplastic lesions, and in the long run even pancreatic cancer. Concerns were also raised as regards a potential increased risk of developing medullary thyroid cancer \[[@CR54]\]. Available data from preclinical and clinical studies are conflicting and no causal relationship has been proven to date between incretin-based therapies, including ExeOW, and an increased risk for any of these pathologies.

The possible association between incretin-based therapies, including ExeOW, and an increased risk of acute pancreatitis has been suggested on the basis of a limited number of postmarketing surveillance reports, which led to limitations in their use in patients with a history of pancreatitis. Findings from animal studies have been inconsistent \[[@CR55], [@CR56]\]. In addition, clinical evidence is available suggesting that patients with T2D may have an increased risk of acute pancreatitis and biliary disease \[[@CR57]\].

Meta-analyses and observational studies assessing the risk of acute pancreatitis during incretin-based therapy indicate an odds ratio (OR) ranging from 0.90 to 0.95 \[[@CR58]--[@CR60]\]. In a meta-analysis of 10 RCTs and three retrospective cohort studies conducted with exenatide the OR for exenatide was 0.84 (95% CI 0.58--1.22) \[[@CR61]\]. A recent systematic review and meta-analysis of 55 randomized and five observational studies \[[@CR62]\] including 353,639 patients receiving incretin-based therapies indicated that the overall incidence of pancreatitis is low (0.11% in RCTs and 0.47% in cohort studies) and that these drugs do not increase the risk of pancreatitis (overall OR in randomized trials of 1.11, 95% CI 0.57--2.17 and OR in observational studies ranging from 0.9 to 1). In particular, the analyses conducted on the two cohort studies involving more than 20,000 patients receiving exenatide showed no increased risk of pancreatitis \[[@CR62]\], the adjusted OR in two observational studies being 0.93, 95% CI 0.63--1.36 in one study \[[@CR58], [@CR59]\] and 0.9, 95% CI 0.6--1.5 in the other \[[@CR60]\].

A potentially increased risk of pancreatic cancer has been also suggested in patients treated with exenatide or sitagliptin on the basis of data from the German and FDA adverse event regulatory databases \[[@CR54], [@CR63]\]. Data from RCTs do not indicate an increased risk for pancreatic cancer with these medicines, and this risk has not been specifically assessed in observational studies or meta-analyses, thus no firm conclusion can be drawn in this regards \[[@CR64]\].

In the summer of 2013 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) finalized a review of GLP-1-based diabetes therapies and concluded that available data do not support the concerns of increased risk of pancreatic adverse events with the use of this class of drugs \[[@CR65]\]. However, concerns in this regard have not ceased and continue to fuel the international debate \[[@CR54], [@CR66], [@CR67]\] and studies to further explore potential risks involving pancreas.

In the meantime it is recommended to educate patients to recognize the symptoms of pancreatitis and to stop taking the medication if these occur. If the workup confirms the diagnosis of pancreatitis, treatment with ExeOW should not be resumed.

The observation of an increased incidence of C cell thyroid carcinoma in rats treated with GLP-1 agonists, including ExeOW, has raised concerns about the possible induction of such neoplasms in humans; actually in the USA (but not in Europe) ExeOW, similarly to all the other GLP-1 agonists, is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2. The human relevance of the thyroid alterations observed in rodents has been questioned as in this species these alterations may spontaneously occur and medullary carcinomas can also be induced with placebo \[[@CR68]\]. Available clinical evidence does not allow definite conclusions in this regard to be drawn. While in RCTs there has been no signal for an excess prevalence of thyroid neoplasms with GLP-1 agonists, data from the FDA adverse event reporting system indicate an excess of reported thyroid cancers with both exenatide and liraglutide \[[@CR54]\]. As these data cannot be considered fully reliable because of lack of control and possible increased reporting triggered by media attention, an active surveillance program for cases of medullary thyroid carcinoma has been implemented in the USA to monitor the annual number and to establish a registry for new cases occurring in patients receiving GLP-1 analogues, including ExeOW \[[@CR69]\].

Patient Acceptance {#Sec25}
------------------

Patient satisfaction is an important variable for the acceptance and ultimately for the efficacy of antidiabetic therapies.

In a survey aimed at assessing patients' attitudes toward a once-weekly injectable therapy in patients with chronic illnesses, glucose-lowering medications administered on a weekly basis were viewed positively by patients with T2D, especially those already treated with injections or dissatisfied with their current treatments or outcomes \[[@CR70]\].

Patient-related outcomes were prospectively evaluated in one open label RCT comparing ExeOW versus ExeBID \[[@CR8], [@CR71]\] and in one double-blind RCT comparing ExeOW versus PIO and SITA \[[@CR12], [@CR72]\]. Diabetes Treatment Satisfaction Questionnaire--status (DTSQ-s) and Impact of Weight on Quality of Life Lite (IWQOL-Lite) were assessed in both studies, over 6-month up to 1-year treatment duration. Within the DURATION-1 study patients in both groups experienced significant and clinically meaningful improvements in treatment satisfaction and QoL which further significantly improved between weeks 30 and 52 for patients switching from ExeBID to ExeOW \[[@CR8]\]. In the DURATION-2 study, the patient-related outcome advantages of ExeOW over SITA and PIO were most notable for the measures of IWQOL-Lite while fewer differences were registered for the more generic QoL measures \[[@CR12], [@CR72]\].

A general willingness to continue ExeOW therapy, despite the need for injections, was reported in relation to the improved flexibility and convenience. The side effects, gastrointestinal and injection site-related, did not affect the treatment satisfaction and adherence to therapy \[[@CR72]\].

A retrospective study using prescription claims data from US patients recently evidenced that GLP-1 receptor agonist-naïve patients were significantly more prone to adhere to a weekly based treatment with ExeOW compared to once-daily LIRA or twice-daily ExeBID \[[@CR73]\].

Positioning of ExeOW in Management of T2D {#Sec26}
=========================================

Early intervention and a personalized stepwise approach are recommended by international guidelines to ensure success in the management of T2D \[[@CR74], [@CR75]\]. Changes in lifestyle and metformin are seen as first-line option; further therapy includes two or more drug combinations. In these algorithms, GLP-1 receptor agonists as monotherapy have a place when metformin is not tolerated or as add-on to metformin if a more marked effect on weight loss and/or a lower risk of hypoglycemia is desirable.

Insulin has been considered for years the best and only option for reducing blood glucose levels when HbA1c is above 9% on oral combinations. Available data indicate that ExeOW is a valid alternative to insulinization, irrespective of HbA1c baseline levels, on the basis of a comparable clinical efficacy versus GLAR \[[@CR74], [@CR76], [@CR77]\]. Combinations of insulin with incretin agents have been explored in RCTs and retrospective studies suggesting that they may offer potential practical advantages including significant A1c lowering and beneficial effects on body weight \[[@CR78], [@CR79]\]. Currently exenatide LAR is not indicated for use in combination with a basal insulin: an RCT is ongoing to evaluate the potential advantages of this combination \[[@CR80]\].

Conclusion {#Sec27}
==========

The recent availability of new classes of medications and drug formulations represents an important improvement in the treatment of T2D. The positioning of GLP-1 receptor agonists has been recently revisited and as such they are regarded not only as appropriate add-on therapy to metformin but also as a valid alternative to basal insulin, even when HbA1c levels are elevated.

Available long-term data, the longest ever reported, clearly indicate that ExeOW treatment can result in a sustained glycemic control and durable weight loss offering long-lasting efficacy associated with modest side effects and not burdened by hypoglycemia or other major unforeseen adverse events in patients choosing to continue on therapy.

Treatment with ExeOW is associated with greater patient satisfaction and improved quality of life, potentially favoring greater patient adherence to therapy.
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